4-Pyridinecarboxamide, N,3-dihydroxy-
![]() |
- $435 - $555.45
- Product name: 4-Pyridinecarboxamide, N,3-dihydroxy-
- CAS: 89640-77-7
- MF: C6H6N2O3
- MW: 154.12
- EINECS:
- MDL Number:MFCD12827778
- Synonyms:4-Pyridinecarboxamide, N,3-dihydroxy-;N,3-Dihydroxyisonicotinamide
4 prices
Selected condition:
Brand
- American Custom Chemicals Corporation
- Apolloscientific
- Crysdot
- Matrix Scientific
Package
- 500MG
- 1g
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberNUC0001264
- Product descriptionN,3-DIHYDROXYISONICOTINAMIDE 95.00%
- Packaging500MG
- Price$555.45
- Updated2021-12-16
- Buy
- ManufacturerApolloscientific
- Product numberOR303880
- Product descriptionN,3-Dihydroxyisonicotinamide
- Packaging500mg
- Price$435
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11025724
- Product descriptionN,3-Dihydroxyisonicotinamide 95+%
- Packaging1g
- Price$524
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number047192
- Product descriptionN,3-Dihydroxyisonicotinamide >95%
- Packaging500mg
- Price$455
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
American Custom Chemicals Corporation | NUC0001264 | N,3-DIHYDROXYISONICOTINAMIDE 95.00% | 500MG | $555.45 | 2021-12-16 | Buy |
Apolloscientific | OR303880 | N,3-Dihydroxyisonicotinamide | 500mg | $435 | 2021-12-16 | Buy |
Crysdot | CD11025724 | N,3-Dihydroxyisonicotinamide 95+% | 1g | $524 | 2021-12-16 | Buy |
Matrix Scientific | 047192 | N,3-Dihydroxyisonicotinamide >95% | 500mg | $455 | 2021-12-16 | Buy |
Properties
Melting point :208-210°
Density :1.504±0.06 g/cm3(Predicted)
pka :7.04±0.10(Predicted)
Density :1.504±0.06 g/cm3(Predicted)
pka :7.04±0.10(Predicted)
Safety Information
Symbol(GHS): |
![]() |
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||
Precautionary statements: |
|